Connect with us

CBD

Medical Cannabis Market Size to Reach USD 24.52 Billion by 2027; Industry Compound Annual Growth Rate of 11.5%

Published

on

Emergen Research Logo

The increasing adoption of medical cannabis for pain management by cancer patients and those with muscle spasms are factors driving the market’s sales growth

VANCOUVER, BC, CANADA, Oct 13, 2021 /EINPresswire.com/ – The global medical cannabis market is expected to be $ 24.52 billion in 2028 with a constant sales CAGR of 11.5, according to the latest analysis by Emergen Research % reach. The increase in medical cannabis products and the increase in research activity are driving the sales growth of the market. In addition, legalization of the product in several countries encourages the growth of the market. The report examines the historical data of the Medical Cannabis market and provides valuable information on its key segments and sub-segments, revenue generation, demand and supply scenario, trends, and other important aspects. Global Medical Cannabis Market report provides complete coverage of the companies’ data including details related to their manufacturing and manufacturing capacity, product portfolio, business overview, revenue, gross profit margin, distribution network and channel, financial condition, and market position.

Medical cannabis is considered safer and has fewer side effects compared to other treatment options. It is used to treat nausea and fight negative side effects, especially in patients undergoing chemotherapy, which makes the whole procedure more bearable. The product is used in conjunction with other opioid pain relievers, which allows patients to reduce the dose and frequency of opioids, and to relieve pain. Legalizing marijuana across the country could create up to 1 million jobs in the US by 2025. Labor is required to grow, process, distribute and sell marijuana and related products. Medical cannabis has not only created jobs, but also generated significant taxes. Colorado, for example, collected more than $ 302 million in taxes and fees for medical and recreational marijuana in 2019.

For Sample Copy of Global Medical Cannabis Market Report Please Visit @ https://www.emergenresearch.com/request-sample/174

The rise in the geriatric population is also fueling market growth as the elderly are more prone to disease and experience high levels of pain. Research and development activities, clinical studies and commercialization of the product will also fuel the market growth. The growth of medicinal cannabis is deterred by certain side effects that patients experience, such as fatigue, dizziness, constipation, and language problems. In addition, the problem of medical cannabis consumption and lack of data security will hamper the growth of medical cannabis.

Market overview:

The research report on the Medical Cannabis market is formulated through extensive primary and secondary research, as well as qualitative and quantitative analyzes of important aspects of the market. The informative data is further validated and verified by the industry experts. The report aims to provide deeper insights into the overall market scenario of the Medical Cannabis Business Area.

The report also examines business strategies and strategic alliances of companies to compete in the marketplace. The report looks at mergers and acquisitions, collaborations, joint ventures, branding and product launches, agreements and partnerships, and corporate and government transactions. The comprehensive analysis of the competitive landscape offers readers a deeper understanding of the competitors.

The top medical cannabis market competitors profiled in the report include:

Canopy Growth Corporation, Aphria, Inc., Aurora Cannabis, Maricann Group, Inc., Tilray, Cronos Group, Organigram Holdings, Inc., Vivo Cannabis, Tikun Olam, and Insys Therapeutics, Inc.
Some key highlights in the report

In October 2020, MediPharm Labs Corp. signed an exclusive supply contract with STADA to meet the growing demand for medical cannabis in Germany. STADA wanted to be the go-to partner for generics, which is achieved through the partnership.
The oil segment is expected to experience significant growth over the forecast period due to the high demand for hemp oil from healthcare workers for clinical purposes. Cannabidiol (CBD) oil can reduce depression and anxiety, relieve cancer-related symptoms, and relieve pain. CBD oil can also treat acne due to its ability to reduce sebum production and anti-inflammatory properties.
Inhalation is a preferred medium of administration because it provides controlled dosage and effective uptake of cannabinoids into the body. The inhalation segment accounted for the largest share of sales in 2020. Inhalation is the most effective and fastest way to induce measurable serum levels of cannabinoids.
For more information on the global Medical Cannabis Market report, please visit @ https://www.emergenresearch.com/industry-report/medical-cannabis-market

The report aims to provide a comprehensive understanding of the medical cannabis market growth and expansion in each key region in the world. It provides accurate estimates of the expected market size and growth over the forecast period 2020-2027.

Regional Analysis of the Medical Cannabis Market:

North America (USA, Canada)
Europe (UK, Italy, Germany, France, rest of the EU)
Asia Pacific (India, Japan, China, South Korea, Australia, rest of APAC)
Latin America (Chile, Brazil, Argentina, rest of Latin America)
Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, rest of MEA)
Emergen Research has segmented the global medical cannabis market by product type, application and route of administration, distribution channel and region:

Product Type Outlook (Revenue, $ Billion; 2018-2028)
oil
Buds
Tinctures
Application Outlook (Revenue, $ Billion; 2018-2028)
Chronic pain
Mental disorders
anorexia
Seizures
Muscle cramp
cancer
Other
Administrative Outlook Route (Revenue, $ Billion; 2018-2028)
Orally
Intravenously
inhalation
Currently
Sales Channel Outlook (Revenue, Billion USD; 2018-2028)
Pharmacies
On-line

For a discount on the global Medical Cannabis Market report please visit @ https://www.emergenresearch.com/request-discount/174

Request the customization of the report: https://www.emergenresearch.com/request-for-customization/174

table of contents

Chapter 1. Methodology & Sources

1.1. Alopecia Market Definition

1.2. Scope of research

1.3. methodology

1.4. Research sources

1.4.1. Primary

1.4.2. Secondary

1.4.3. Paid sources

1.5. Alopecia Market Estimation Technique

Chapter 2. Summary

2.1. Summary snapshot, 2021-2028

Chapter 3. Key Findings

Chapter 4. Alopecia Market Segmentation and Impact Analysis

4.1. To analyze the material segmentation of the Alopecia Market

4.2. Industrial outlook

4.2.1. Analysis of Alopecia Market Indicators

4.2.2. Analysis of the Alopecia Market Drivers

4.2.2.1. Rapid urbanization and industrialization

4.2.2.2. Strict government regulations regarding CO2 emissions

4.2.2.3. Increasing prevalence of respiratory diseases

4.2.2.4. Increasing need to improve indoor air quality

4.2.3. Analysis of Alopecia Market Restrictions

4.2.3.1. High costs associated with maintaining alopecia products

4.2.3.2. Availability of renewable energy sources

4.3. Technological insights

4.4. Legal framework

4.5. Porter’s Five Forces Analysis

4.6. Competitive metric space analysis

4.7. Price trend analysis

4.8. Covid-19 impact analysis

Continuation….

Key questions answered in the report:

What is the growth rate of the medical cannabis market? What is the expected market valuation of the medical cannabis industry through 2027?

What are the major growth drivers and restraining factors in the medical cannabis market?

Who are the main players in the market? What are the main strategies of these companies?

Key Benefits Of Buying The Global Medical Cannabis Report:

Comprehensive analysis of the changing competitive landscape
Helps in decision making processes for the companies along with detailed strategic planning methods
The report offers an 8-year forecast and assessment of the global medical cannabis market
Helps in understanding the key product segments and their estimated growth rate
In-depth analysis of market drivers, restraints, trends and opportunities
Comprehensive regional analysis of the global medical cannabis market
Proceed with the purchase: https://www.emergenresearch.com/select-license/174

Thank you for reading our report. If you have any requests to customize the latest report, please contact us. Our team will assist you and ensure that the report meets your requirements.

Read similar reports from Emergen Research:

Nanopharmaceutical Drugs Market @: https://www.emergenresearch.com/industry-report/nanopharmaceutical-drugs-market

Clinical Perinatal Software Market @: https://www.emergenresearch.com/industry-report/clinical-perinatal-software-market

Human Microbiome Modulators Market @: https://www.emergenresearch.com/industry-report/human-microbiome-modulators-market

In Silico Drug Discovery Market @: https://www.emergenresearch.com/industry-report/in-silico-drug-discovery-market

About us:

At Emergen Research, we believe in technological advancement. We are a growing market research and strategy consultancy with a comprehensive knowledge base of cutting-edge and potentially market-changing technologies that are expected to become more widespread in the coming decade.

Eric Lee
Emergen Research
+91 90 210 91709
sales@emergenresearch.com
Visit us on social media:
Facebook
Twitter
LinkedIn

You just read:

News provided by

October 13, 2021 at 2:19 pm GMT


EIN Presswire’s priority is source transparency. We don’t allow opaque clients, and our editors try to carefully weed out false and misleading content. If, as a user, you notice something that we have overlooked, please make us aware of it. Your help is welcome. ONE Presswire, Everyone’s Internet News Presswire ™, seeks to define some of the boundaries that are appropriate in the world today. Please see our editorial guidelines for more information.

Submit your press release

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

CBD

ASA rules unfavourably towards CBD oil’s immune health supporting role

Published

on

In the presentation for ProLife CBD Oils, the UK company also claimed that the product was beneficial to general well-being and the immune system, which also means that it has been approved by the Food Standards Agency.

In response to the ASA’s ruling, Gemporia said they were unable “to substantiate the claims or to demonstrate that they are approved claims on the UK Nutrition and Health Claims Register (NHC) (the NHC Register). “

The company added that it assumed the products would be allowed to be marketed because a novel food application had been submitted to the FSA.

All references to this were based on this assumption, adding that they misunderstood the context.

Redditch-based Gemporia admitted having violated the Code on all counts and said their future advertising would comply with the Code.

Presentation details

The ad was specifically a 48-minute teleshopping presentation that aired on Jan.

Throughout the presentation, speakers made claims, including from field reports of the benefits of CBD oil, suggesting that the product could relieve pain and chemotherapy-induced nausea.

The presentation also discussed the requirement that CBD products must be registered with the FSA, saying, “… you have the Certificate of Analysis here and the stability report check … everyone has to have it” and “… what they say is anyone who has submitted their application before the deadline allow them to proceed because they have spent the money and tried and you hope that when they have done so they are confident “,

They continued, “… all this UK regulation just happened, a lot of companies can’t even bring you CBD right now because it doesn’t qualify for quality.”

“We always had the quality; we didn’t have to change anything “and” … this quality certificate and all ticks were always there. “

In support of their decision, ASA said the products were still being tested by the FSA and the novel food application process took into account factors other than the quality of the product.

They concluded that the ad “misrepresents the requirements for novel food approval and misleadingly implies that ProLife CBD Oil products have been approved, endorsed, or approved by the FSA.”

Prevents, treats and cures diseases

ASA’s assessment also assumed that consumers understood that the presentation said ProLife CBD oils could help with the medical conditions mentioned in the slides, testimonials, and speakers.

“We concluded that the claims implied that the product was a food that prevented, treated or cured a human disease, which was prohibited by the Code,” they added.

We thought viewers would understand the claim “helps your immune system” to mean that the CBD in the product would help the immune system function effectively.

“The claim was therefore a specific health claim that is not entered in the NHC register and therefore violates the code.

The other claim, “Helps general well-being”, was also considered to be a general health claim that had to be accompanied by a specific approved health claim related to CBD.

However, since there were no approved health claims for CBD, this claim also violated the code.

Continue Reading

CBD

Feds highlight cannabis research barriers (Newsletter: October 26, 2021)

Published

on

TX Delta 8 ban survives first judicial challenge; Top NV Legislators: Feds Must Legalize Marijuana; Psychedelics grants awarded

Sign up to receive the Marijuana Moment newsletter in your inbox every weekday morning. It’s the best way to make sure you know what cannabis stories are running through your day.

Your support makes marijuana moment possible …

Free to read (but not free to produce)! We pride ourselves on our newsletter and coverage we publish at Marijuana Moment and are happy to make them available to you free of charge. But it takes a lot of work and resources to achieve this.

  • P. Aiden Hunt, Editor, Profiles in Legalization: “MarijuanaMoment.net is probably your best source for cannabis policy news. It caters to the same highly specialized audience that I aim for with my own writing; People affected by the details of cannabis policy. Reading the newsletter assures me that I have not missed anything in my own search. “

If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and benefit more readers: https://www.patreon.com/marijuanamoment

/ MOST IMPORTANT THINGS

In a new report from Marijuana Moment, the National Institute on Drug Abuse briefed the House and Senate Budget Committees on how the restrictive status of cannabis in Appendix I can “hamper critical research … or prevent scientists from pursuing such work”.

  • NIDA also told Congress that scientists fail to study the marijuana consumers actually buy from pharmacies “may hinder the study of the health effects of products that individuals use in the real world.”

A Texas judge turned down an initial motion to block regulators’ ban on delta-8 THC from hemp. The case will be retried next month.

Nevadas Assembly Speakers pro tempore wrote a comment extolling the state’s success in regulating marijuana in a “fair and business-friendly setting” – but said that state legalization was needed to “take this work to the next level”.

the Plant Medicine Coalition announced that it has awarded approximately $ 50,000 in grants to support a variety of psychedelics projects – including one to combat “abuse and predatory behavior in herbal medicine circles”.

/ FEDERATION

the White House National Drug Control Policy Office released details of a new drug control strategy between the US and Colombia.

A Federal Court of Justice Will determine whether to reimburse Missouri medical cannabis sales of $ 166,000 confiscated in transit in Kansas.

Majority Leader in the Senate, Chuck Schumer (D-NY) tweeted about moving to New York to clear up previous marijuana convictions, saying, “I’m proud to see NY take this step. And I’m working with @SenBooker & @RonWyden to pass our Cannabis Administration and Opportunity Act to end the marijuana ban, pass criminal law reforms, and undo the harms of the war on drugs at the federal level. “

Representative Dave Joyce (R-OH) tweeted: “Americans in a majority of states, in both red and blue, have voted to pass sensible cannabis reforms. I encourage my colleagues to respect the will of their voters and the rights of their states and to work for these reforms at the federal level. “

/ CONDITIONS

Pennsylvania Governor Tom Wolf (D) tweeted: “We are working on legalizing marijuana in Pennsylvania. In the meantime, let’s pardon marijuana offenses as soon as possible. ”Separately, Democratic candidate for governor Josh Shapiro, currently the attorney general, tweeted, “It is time to legalize marijuana. To regulate and tax it. But let me be clear: we need to clear the records of those who served sentences other than legalization for possessing small amounts of marijuana. That is the way to justice. “

New Jersey Governor Phil Murphy (D) tweeted, “We have brought four new industries to New Jersey – offshore wind, film and television, marijuana, and sports betting. These industries will bring thousands of well-paying jobs to the Garden State. “

Illinois’s The lieutenant governor held a meeting on a cannabis tax-funded grant program.

Florida Democratic gubernatorial candidate Charlie Crist, currently Congressman, tweeted a video of himself speaking of his support for the legalization of marijuana.

Maryland Democratic attorney general candidate Anthony Brown, currently Congressman and former lieutenant governor, promoted his previous work on decriminalizing marijuana.

Connecticuts The House of Representatives minority leader received an award from the prohibition organization Smart Approaches to Marihuana.

the South Dakota The legislature’s preliminary marijuana study committee will meet on Wednesday.

the Massachusetts The Supreme Court agreed to hear a case over the validity of a local ban on the sale of marijuana.

A Virginia The judge defended his detention of a woman who admitted smoking marijuana the day before before testifying against her alleged domestic violence perpetrator.

Oregon The Department of Agriculture is recruiting volunteers to serve as temporary commissioners in the new Oregon Hemp Commission.

Colorado Regulatory agencies approved additional pesticides that can be used on cannabis.

New Mexicos The Department of Agriculture tweeted about a state hemp poll.

Texas Regulators released an updated list of registered hemp laboratories.

West Virginia Regulators will be hosting events next week to enroll patients with medical cannabis.


Marijuana Moment pursues more than 1,200 cannabis, psychedelics, and drug bills in state legislatures and in Congress this year. Patreon backers who have pledged at least $ 25 per month will have access to our interactive maps, charts, and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a Patreon supporter to gain access.

/ LOCAL

Oakland, California Regulators have referred some social equity marijuana licensees to the city’s collections department after defaulting on loans.

/ INTERNATIONAL

India The Union Ministry of Social Justice and Empowerment recommends decriminalizing drug possession.

Canada The Mexican Embassy tweeted, “Hemp seeds are known as #superfoods because of their many health benefits. Hemp can help care for your skin, control sugar levels, and maintain healthy cholesterol levels. “

The Chief Police Constable in Cleveland, Yorkshire, England posted a comment calling for an end to the war on drugs.

A former guernsey The Prime Minister said it was time to legalize marijuana.

/ SCIENCE & HEALTH

A study of more than 100 cannabis samples showed that “Sativa and Indica-labeled samples” genetically indistinct on a genome-wide scale. “

A review of research on adolescent marijuana use found that the “lifelong prevalence of Vaporizing cannabis doubled from 2013 to 2020 (6.1% to 13.6%), consumption in the last 12 months doubled from 2017 to 2020 (7.2% to 13.2%) and the 30-day prevalence of Cannabis vaping increased sevenfold from 2013 to 2020 (1.6.). % to 8.4%). “

/ RESPONSIBILITY, OPINION & ANALYSIS

the Alliance for Drug Policy seeks several positions including a manager of “Drug Market Reform Strategy and Government” and a coordinator of California’s drug decriminalization efforts.

the Tax foundation criticized a voting initiative in Colorado to raise marijuana taxes and use the proceeds to fund educational programs.

the Vermont Cannabis Equity Coalition Recommendations issued to regulators.

/ COMPANIES

A Florida judge one-sided with Leafly Lift regulators’ ban on using third-party apps to order medical cannabis.

MedMen Enterprises Inc. has a new Chief Operating Officer.

Cresco Labs announced that its Social Justice Summer Initiative raised more than $ 250,000 for judicial reform organizations and supported the extermination process of more than 1,000 people with marijuana criminal records.

Many top Wall Street banks discontinue marijuana testing prior to hiring.

/ CULTURE

Lil ‘Kim introduces a cannabis brand.

Make sure to subscribe to receive Marijuana Moment in your inbox every day.

Photo courtesy of Chris Wallis // side pocket images.

Marijuana Moment is made possible with the support of readers. If you rely on our cannabis journalism to keep up to date, please consider making a monthly Patreon Pledge.

Continue Reading

CBD

Columbia Care partners with international superstar Pitbull to launch N2P, a new line of full spectrum CBD wellness products — Greenway Magazine

Published

on

Designed for those with a health and wellness focus, the new line harnesses all of the power of the hemp plant for an enhanced experience and is now available online and at select Columbia Care pharmacies

Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced growers, manufacturers, and distributors of cannabis and from Hemp-derived CBD products in the United States and international superstar Pitbull today announced the launch of N2P – a new line of high-quality, full-spectrum CBD products for those looking to incorporate CBD into their health and wellness routines. N2P tries to change the negative perception of CBD products and to put the potential of these products in a positive light, what N2P stands for: negative to positive.

“We are committed to changing the way people talk about CBD and offering a line of products that people can trust and expect to get the best experience possible,” said Jesse Channon, Columbia Care’s chief growth officer. “We are because of his passion entered into a partnership with Pitbull for CBD and its high quality. Together we are working to introduce premium full-spectrum CBD products for customers who are passionate about health and wellness, but also for those who are curious about CBD and have not tried it before – we want everyone to be able to change negatively too positive. “

The N2P product line has been formulated with quality in mind. These products are made from natural hemp grown in the USA and are specifically designed to use the plant’s full potential to support daily well-being, such as: The first product offering includes lip balms, ointments, tinctures and sour gums. Chocolate products will hit the market later in 2021.

“I am honored to be partnering with Columbia Care to announce our new line of CBD, N2P (Negative to Positive),” said Armando Christian Perez (Pitbull). “N2P is an all natural, high quality product that is geared towards the therapeutic benefits of CBD. It’s designed to help clients stay focused, positive, and feel at their best. Our goal is to change the perception of the health and wellness benefits of CBD products. We look forward to sharing N2P with fans around the world, Dale! “

At the start, the N2P line includes:

  • 3-pack Pina Colada lip balm (150mg CBD, 50mg per balm)
  • 2oz Relief Ointment (250mg CBD)
  • 1oz star fruit tincture (1,000 mg CBD, 33.3 mg CBD per serving)
  • 30ct. Gums (750 mg CBD, 25 mg per gum)

N2P products will be available to purchase online in select states at www.n2pwellness.com and at select Columbia Care pharmacies in Delaware, Maryland and New York. They’ll also be available at The Green Solution pharmacies in Colorado later this year.

About Columbia Care

Columbia Care is one of the largest and most experienced breeders, manufacturers, and providers of cannabis products and related services licensed in 18 US jurisdictions and the EU. Columbia Care operates 130 facilities including 99 pharmacies and 31 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original medical cannabis suppliers in the United States and now provides industry leading products and services to both the medical and adult markets. In 2021, the company launched Cannabist, its new retail brand, and created a national pharmacy network using proprietary technology platforms. The company offers products made from flowers, edibles, oils and tablets, and makes popular brands such as Seed & Strain, Triple Seven, gLeaf, Classix, Press, Amber and Platinum Label CBD. For more information on Columbia Care, please visit www.col-care.com.

Beware of forward-looking statements

This press release contains certain statements that constitute forward-looking information within the meaning of applicable securities laws and that reflect the company’s current expectations about future events. The Company has made assumptions about its ability to execute brand and product initiatives that, while deemed appropriate by the Company, may prove to be incorrect and subject to known and unknown risks and uncertainties that will lead to actual results, performance or accomplishments The company could differ materially from those expressed or implied in any forward-looking information. Securityholders should review the risk factors discussed under “Risk Factors” on the Columbia Care Annual Information Form dated March 31, 2021, filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com and described from time to time in documents submitted by. the company will be filed with the Canadian securities regulators.

Continue Reading
Advertisement

Trending